12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Omecamtiv mecarbil: Phase II ongoing

Cytokinetics said an IDMC recommended continuation to the second cohort of the double-blind, placebo-controlled, international Phase IIb ATOMIC-AHF trial of omecamtiv mecarbil based on a safety review. The trial, which plans to enroll about...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >